Idera Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The stock decreased 7.22% or $0.38 during the last trading session, reaching $4.88. The stock was purchased at an average cost of $1.50 per share, for a total transaction of $12,000,000.00.
Heading into the stock price potential, BioCryst Pharmaceuticals, Inc. needs to grow just 59.77% to cross its median price target of $8.5. It has outperformed by 4.43% the S&P500. Swiss National Bank now owns 114,300 shares of the biotechnology company's stock valued at $960,000 after buying an additional 18,000 shares during the period.
Royal Bank of Canada upgraded shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) from a sector perform rating to an outperform rating in a research report report published on Tuesday, January 2nd, Marketbeat Ratings reports. The stock's market capitalization is $410.15 million.
The stock decreased 0.48% or $0.07 during the last trading session, reaching $14.56. Blackrock has 1,125 shares. General Motors Company (NYSE:GM) has risen 7.92% since January 23, 2017 and is uptrending.
Since August 22, 2017, it had 0 insider purchases, and 1 insider sale for $57,168 activity. Finally, analysts have given a mean recommendation of 1.70 on this stock (A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range). Therefore 100% are positive. BioCryst Pharmaceuticals had 33 analyst reports since August 7, 2015 according to SRatingsIntel. Needham & Company LLC restated a "hold" rating on shares of BioCryst Pharmaceuticals in a report on Wednesday, April 12th. HC Wainwright restated a "buy" rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a report on Wednesday, November 8th. The company was upgraded on Wednesday, January 6 by Jefferies. See Idera Pharmaceuticals, Inc.
On 9/18/2017 Fred E Cohen, Director, sold 54,250 with an average share price of $5.42 per share and the total transaction amounting to $294,035.00. Finally, Noble Financial restated a "buy" rating on shares of BioCryst Pharmaceuticals in a report on Sunday, May 28th. Bancorp Of Mellon Corp has invested 0% in Idera Pharmaceuticals, Inc. RBC Capital Markets maintained BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have moved within the range of $3.95 to $9.25. Its up 0.01, from 1.68 in 2017Q2.
A number of hedge funds have recently added to or reduced their stakes in the business. BioCryst Pharmaceuticals earned a news sentiment score of 0.09 on Accern's scale. (NASDAQ:BCRX). 12,000 are owned by Pillar Pacific Ltd Liability. Moreover, Goldman Sachs Gp has 0% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 3.12 million shares. Susquehanna Group Ltd Liability Partnership stated it has 38,923 shares or 0% of all its holdings. Rhumbline Advisers holds 0% or 95,458 shares. California State Teachers Retirement Sys holds 128,045 shares. Hudbay Minerals Inc (NYSE:HBM) has a Return on Assets (ROA) of 0.
Earlier in the day, it was announced that Idera Pharmaceuticals would be merging with BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Acuta Cap Prns Lc holds 0.94% or 996,300 shares in its portfolio.
North Star Inv Mngmt Corporation, Illinois-based fund reported 585,275 shares. 0 funds opened positions while 1 raised stakes. JMP Securities maintained BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 47,367 shares. Emory University owns 360,042 shares. (NASDAQ:BCRX) to report earnings on February, 26. The New York-based Blackrock has invested 0% in BioCryst Pharmaceuticals, Inc. The current EPS for the company has been recorded at $-0.34. Dynegy Inc. (DYN) average trading volume of 3,684,650 during the past month is 17.42% below its average volume over the past year, indicating that investors have been less active than usual in the stock in recent times. Jennison Associates LLC now owns 1,844,636 shares of the biotechnology company's stock valued at $15,495,000 after buying an additional 489,536 shares during the period. Alyeska Gru Lp accumulated 635,853 shares. Franklin Street Advisors Inc Nc holds 49,000 shares or 0.04% of its portfolio. Marietta Ptnrs Ltd Liability has 37,872 shares for 0.46% of their portfolio. Los Angeles Capital Mgmt And Equity Research holds 0% or 25,170 shares. (NASDAQ:BCRX) for 10,189 shares. It was reported on Jan, 24 by Barchart.com. The firm has "Buy" rating given on Thursday, November 16 by H.C. Wainwright. Jefferies has "Hold" rating and $12 target. JPMorgan Chase & Co. boosted its stake in shares of Idera Pharmaceuticals by 45.4% in the 3rd quarter. (NASDAQ:BCRX) has "Overweight" rating given on Wednesday, September 6 by JP Morgan. The stock has "Buy" rating by Jefferies on Wednesday, September 6.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.
Devon Energy (DVN) Downgraded to Hold at KLR Group
Devon Energy Corporation (DVN ) pays a dividend of 0.24, which translates to dividend yield of 0.54% based on the current price. Advisor Prns Limited Liability Company stated it has 1.01% of its portfolio in Bank of America Corporation (NYSE:BAC).
Abbott Laboratories (ABT) Issues Q1 Earnings Guidance
The stock of Abbott Laboratories (NYSE: ABT ) has "Outperform" rating given on Friday, October 9 by RBC Capital Markets. Fairpointe Capital Llc bought 55,682 shares as the company's stock declined 1.87% while stock markets rallied.